Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PembroRad: Pembrolizumab vs Cetuximab with RT in HNSCC
NCT02707588Phase 2Completed
- Sponsor
- GORTEC
- Start
- May 2016
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by GORTEC. Primary endpoint: Locoregional Control at 15 months. Started May 2016; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02707588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02707588.